Tag Archives: NAT

Nordic American Tanker (NAT) was Downgraded to a Hold Rating at Cleaves Securities

In a report issued on October 14, Joakim Hannisdahl from Cleaves Securities downgraded Nordic American Tanker (NAT – Research Report) to Hold, with a price target of $4.10. The company’s shares closed last Monday at $4.00. According to TipRanks.com, Hannisdahl

B.Riley FBR Keeps a Buy Rating on Nordic American Tanker (NAT)

B.Riley FBR analyst Liam Burke maintained a Buy rating on Nordic American Tanker (NAT – Research Report) on August 16 and set a price target of $4.75. The company’s shares closed last Monday at $1.76, close to its 52-week low

Nordic American Tanker (NAT) Gets a Buy Rating from Cleaves Securities

Cleaves Securities analyst Joakim Hannisdahl reiterated a Buy rating on Nordic American Tanker (NAT – Research Report) on August 16 and set a price target of $3.30. The company’s shares closed last Monday at $1.76, close to its 52-week low

Analysts Offer Insights on Services Companies: Nordic American Tanker (NYSE: NAT), Reading International Inc (NASDAQ: RDI) and TEGNA Inc (NYSE: TGNA)

There’s a lot to be optimistic about in the Services sector as 3 analysts just weighed in on Nordic American Tanker (NAT – Research Report), Reading International Inc (RDI – Research Report) and TEGNA Inc (TGNA – Research Report) with

Wednesday’s Midday Stock Update: American Green Inc (ERBB), Nordic American Tanker (NAT), NovaBay Pharma (NBY), Advaxis (ADXS), Xoma Corp (XOMA)

So far Wednesday, May 15, NASDAQ is up 3.85% and the S&P is up 3.19%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; American Green Inc (ERBB – Research Report), Nordic American Tanker

Wednesday’s Midday Movers: American Green Inc (ERBB), Nordic American Tanker (NAT), NovaBay Pharma (NBY), Advaxis (ADXS), Xoma Corp (XOMA)

So far Wednesday, May 15, NASDAQ is up 3.85% and the S&P is up 3.26%. Here are this morning’s most active stocks: American Green Inc (ERBB – Research Report), Nordic American Tanker (NAT – Research Report), NovaBay Pharma (NBY –